Hartmann D, Mosberg H, Weber W
Pharma Clinical Research, F. Hoffmann-La Roche, Basel, Switzerland.
Dermatologica. 1989;178(1):33-6. doi: 10.1159/000248383.
A possible influence of the aromatic retinoid acitretin on the hypothrombinemic action of phenprocoumon was investigated in 10 healthy male volunteers, 22-33 years of age. In a run-in period of 17 days the prothrombin complex activity (Quick) of the subjects was adjusted by individual doses of phenprocoumon (range 1.5-3 mg/day) to a therapeutic level of around 20% (INR = 3.6). Afterwards the dosage regimens were kept unchanged until day 40 when 60 mg oral vitamin K1 were administered. From day 18 to day 28 once daily doses of 50 mg acitretin were applied concurrently with phenprocoumon. The mean (+/- SD) prothrombin complex activity increased slightly and steadily from 19 +/- 1% on day 10 over 22 +/- 1% on day 18 to 24 +/- 4% on day 28 and reached 27 +/- 4% on day 38 (the corresponding INRs were 3.30, 2.91, 2.71 and 2.46 respectively). There were, however, no relevant changes of the Quick values in any subject which could be attributed to acitretin. It can be concluded that, under the present experimental conditions, acitretin did not affect significantly the anticoagulant action of phenprocoumon.
在10名年龄在22至33岁的健康男性志愿者中,研究了芳香维甲酸阿维A对苯丙香豆素降凝血酶原作用的可能影响。在为期17天的导入期内,通过给予个体剂量的苯丙香豆素(范围为1.5 - 3毫克/天),将受试者的凝血酶原复合物活性(Quick)调整至约20%(国际标准化比值[INR]=3.6)的治疗水平。此后,剂量方案保持不变,直到第40天给予60毫克口服维生素K1。从第18天到第28天,每天一次给予50毫克阿维A,并与苯丙香豆素同时服用。凝血酶原复合物活性的平均值(±标准差)从第10天的19±1%稳步小幅上升至第18天的22±1%、第28天的24±4%,并在第38天达到27±4%(相应的INR分别为3.30、2.91、2.71和2.46)。然而,任何受试者的Quick值均未出现可归因于阿维A的相关变化。可以得出结论,在当前实验条件下,阿维A对苯丙香豆素的抗凝作用没有显著影响。